Darzalex, Ibrance among latest SMC decisions
The Scottish Medicines Consortium (SMC) has announced its latest round of decisions for NHS Scotland, publishing advice accepting three new medicines.
Read More
Tag: daratumumab
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More
Janssen unveils new data backing wider use of Darzalex
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Read More
Janssen bags new EU approval for Darzalex
Janssen’s Darzalex has been approved in Europe for the first-line treatment of patients with multiple myeloma.
Read More
Darzalex combo wins nod for newly diagnosed multiple myeloma
Janssen’s Darzalex has become the first monoclonal antibody to be approved in the US to treat patients newly diagnosed with multiple myeloma.
Read More
NICE approves CDF funding for Janssen’s Darzalex
The National Institute for Health and Care Excellence (NICE) is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund (CDF) for some adults with previously treated multiple myeloma.
Read More
Darzalex, Epclusa will be funded on NHS Scotland
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
Read More
EU expands use of Janssen’s Darzalex
EU regulators have expanded the scope of Janssen’s Darzalex to include patients with multiple myeloma who have received at least one prior therapy, when given in combination with lenalidomide and dexamethasone, or bortezomib (Velcade).
Read More
NICE set to reject Janssen’s Darzalex for multiple myeloma
Janssen said it is extremely concerned that the National Institute for Health and Care Excellence has not recommended Darzalex for treatment of relapsed and refractory multiple myeloma in adults in preliminary guidelines.
Read More
Janssen seeks to expand use of multiple myeloma drug
Janssen Biotech is seeking to expand the scope of Darzalex as a second-line combination treatment for multiple myeloma.
Read More
J&J’s Darzalex improves outcomes in multiple myeloma trial
Adding Johnson & Johnson’s Darzalex to the standard regimen of Takeda’s Velcade and dexamethasone significantly improved outcomes for patients with recurrent or refractory multiple myeloma, show findings of a late-stage trial.
Read More
Janssen’s Darzalex gets conditional nod for multiple myeloma
Janssen’s Darzalex has received a condition approval in Europe for the treatment of multiple myeloma, offering patients with the disease access to a novel active immunotherapy.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
